Раздел 1.21. Folpe A.L., Inwards C.Y. Bone and soft tissue pathology (A volume in the series foundations in diagnostic pathology. Series editor: J.R. Goldblum) // Saunders Elsevier, Philadelphia. 2010. 462 P. 2. Алиев М. Д. Злокачественные опухоли костей. М.: Издательская группа РОНЦ, 2008. 408 с.:187, ил. 3. Соловьев Ю.Н., Долгушин Б.И., Лукьянченко А.Б., Кочергина Н.В., Ширяев С.В., Рыжков А.Д. Диагностика первичных злокачественных опухолей костей // В кн.: «Злокачественные опухоли костей» (под ред. М.Д. Алиева) Издательская группа РОНЦ им. Н.Н. Блохина РАМН. М., 2008. С. 55–141.4. Mirra J.M., Brien E.W. Giant notochordal hamartoma of intraosseous origin: a newly reported benign entity to be diatinquished from chordoma. Report of two cases // Skeletal Radiol. 2001. Vol. 30. Р. 698-709. 5. Evans H.L., Raymond A.K., Ayala A.G. Vascular tumors of bone: a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high grade angiosarcoma // Hum. Pathol.2003. Vol. 34. Р.680-689. 6. Mandahl N., Gustafson P., Mertens F. et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma // Genes Chromosomes Cancer. 2002. Vol.33, p.188-200.7. Kilpatrick S.E., Geisinger K.R., King T.S. et al. Clinicopathologic analysis of HER-2/neu immunoezpression amang various histologic subtupes and grades of osteosarcoma // Mod. Pathol.2001. Vol.14, p.1277-1283.8. Виноградова Т.П. Международная классификация опухолей с комментариями // Архив патологии, 1975;37(2):34-7.9. Обзор SEER 1975–2008 годов, (Surveillance, Epidemiology, and End Results (SEER) Statistics Review, 1975 -2008; based on November 2010 SEER data submission, posted to the SEER website in 2011.10. Bray F, Colombet M, Mery L, et al., editors. Cancer incidence in five continents. Volume XI. Lyon (France): International Agency for Research on Cancer; 2017. (IARC Scientific Publication No. 166).11. H. Haibach, C. Farrell, F. J. Dittrich. Neoplasms arising in Paget's disease of bone: a study of 82 cases. Am J Clin Pathol. 1985. May; 83(5):594-600.12. A.G. Huvos, A. Butler, S.S. Bretsky. Osteogenic sarcoma associated with Paget's disease of bone. A clinicopathologic study of 65 patients Cancer, 1983. Oct 15;52(8):1489-95.13. M.R. Wick, G.P. Siegal, K.K. Unni, R.A. McLeod, H.G. Greditzer. 3rd Sarcomas of bone complicating osteitis deformans (Paget's disease): fifty years' experience Am J Surg Pathol. 1981. Jan;5(1):47-59. 14. B. Widhe 1, T. Widhe. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000. May;82(5):667-74.15. R.J .Grimer 1, T.W.R. Briggs. Earlier diagnosis of bone and soft-tissue tumours J Bone Joint Surg Br. 2010. Nov;92(11):1489-92.16. A. M. Malhas 1, R. J. Grimer, A. Abudu, S. R. Carter, R. M. Tillman, L. Jeys. The final diagnosis in patients with a suspected primary malignancy of bone J Bone Joint Surg Br. 2011. Jul;93(7):980-3.17. Clara Benna 1 2, Andrea Simioni 1, Sandro Pasquali 1 3, Davide De Boni 1, Senthilkumar Rajendran 1, Giovanna Spiro 1, Chiara Colombo 3, Calogero Virgone 4, Steven G DuBois 5, Alessandro Gronchi 3, Carlo Riccardo Rossi 1 6, Simone Mocellin 1 6. Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. Oncotarget 2018. Apr 6;9(26):18607-18626.18. G.M. Smith., G.D. Johnson, R.J. Grimer, S.Wilson. Trends in presentation of bone and soft tissue sarcomas over 25 years: little evidence of earlier diagnosis. Ann R Coll Surg Engl. 2011 Oct;93(7):542-7.19. Bovee J.V.M.G., Lambert J.C.M., van den Broek J.C.M., Cleton-Jansen A.-M., Hogendoorn P.C.W. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma // Lab. Investig. 2000. Vol.80, N.12, p.1925-1934. 20. Zhang H., Oliveira A.M. Fusion genes in epithelial neoplasia. J.Clin. Pathol. 2010 Jan; 63(1):4-11 Epub 2009 Jul 28. 21. Mitelman F., Johansson C., Mertens F., eds. Mitelman database of chromosome aberrations in cancer (2004) Updated 5-26-04. Retrieved July 27, 2004, from World Wide Web: http: // cgap.nci.nih.gov / Chromosomes / Metelman. 22. Oliveira A.M., Nascimento A.G., Lloyd R.V. Leptin and leptin receptor mRNA are widely expressed in tumors of adipocytic differentiation // Mod. Pathol.2001. Vol.14, p. 549-555.23. Bridge J.A., Bhatia P.S., Anderson J.R., Neff J.R. Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions // Cancer Genet. Cytogenet.-1993.-Vol.69.-p.79-90. 24. Fletcher J.A., Gebhardt M.C., Kozakewich H.P. Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes // Cancer Genet. Cytogenet. 1994. Vol.77, p. 81-88. 25. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA // Cell Biol. 2007.Vol. 26, p. 1-18. 26. Stock C., Kager L., Fink F.M., Gadner H., Ambros P.F. Chromosomal regions involved in the pathogenesis of osteosarcomas // Genes Chromosomes Cancer. 2000.Vol. 28, p. 329-336. 27. Tarkkanen M., Knuutila S. The diagnostic use of cytogenetic and molecular genetic techniques in the assessment of small round cell tumors // Curr. Diagnostic. Pathol. 2002. Vol. 8, p. 338-348. 28. Kawashima A., Okada Y., Nakanishi I., Ueda Y., Iwata K., Roessner A. Immunolocalization of matrix metalloproteinases and tissue inhibitors of 379 metalloproteinases in human chondrosarcomas // Gen. Diagn. Pathol. 1997. Vol. 142, p.129-137.29. Ladanyi M., Gerald W.L. Present and potential impact of expression profiling studies of human tumors. In: Ladanyi M., Gerald W.L., eds. Expression profiling of human tumors. Diagnostic and research applications. Totawa N.J.: Huvana Press. 2003, p. 3-7. 30. Llombart-Bosch A. Ewing’s sarcoma and Primitive Neuroectodermal Tumor of Bone and soft tissue // Int. J. Surg. Pathol. 1999. Vol.7, N 4, p.185-192. 31. Huang H-Y., Illei P.B., Zhao Z. et al. Ewing’s sarcoma with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse // J. Clin. Oncol. 2005. Vol.23, N 3, p. 548-558. 32. Burchill S.A. Ewing’s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities // J. Clinical Pathology. 2003. Vol. 56, p.96-102. 33. Heiser D., Labi V., Erlacher M, et al. The Bcl-2 protein family and its role in the development of neoplastic disease // Exp/ Gerontol. 2004. Vol. 39, p.1125-1135. 34. Tallini G., Dorfman H., Brys P. et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group // J. Pathol. 2002. Vol. 196, p.194-203. 35. Shen Z.N., Nishida K., Doi H. et al. Suprassion of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21 // Biochem. Biophys. Res. Commun. 2005. Vol. 328, N2, p.375-382. 36. Hazelbag H.M., Fleuren J.G., van den Broek L.J. et al. Adamantinoma of long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis // Am. J. Surg. Pathol.1993. Vol.17, p.1225-1233. 37. Casali P.G., Bjelack S., Abecassis N. Oncol. 2018 Oct 1;29(Suppl 4)38. Bonar S.F., Watson G., Gragnaniello C., Seex K., Magnussen J., Earwaker J., Intraosseous hibernoma: characterization of five cases and literature review Skeletal Radiol. 2014 Jul;43(7):939-46.39. Bus M.P.A. Campanacci D., Albergo J.I. et al. Conventional Primary Central Chondrosarcoma of the Pelvis: Prognostic Factors and Outcome of Surgical Treatment in 162 Patients J Bone Joint Surg Am J Bone Joint Surg Am 2018 Feb 21;100(4):316-32540. Amaray F., Perez-Casanova L., Ye Hongtao et al., Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement Mod Pathol. 2019 Dec;32(12):1762-1771.41. Dahlin D.C., Bertoni F., Beabout J.W., Campanacci M. Fibrocartilaginous mesenchymoma with low-grade malignancy Skeletal Radiol. 1984;12(4):263-9.42. Yoshida Ken-Ichi, Nakano Y., Kitahara M.H. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone Mod Pathol. 2019 Dec;32(12):1751-1761.43. Neuville A., Chibon F., Coindre J.-M. Grading of soft tissue sarcomas: from histological to molecular assessment Pathology. 2014 Feb;46(2):113-20.44. Eefting D., Schrage Y.M., Geimaerdt M.J.A. et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors Am J Surg Pathol. 2009 Jan;33(1):50-7.45. Magham D.C., Athanasou N.A. Guidelines for histopathological specimen examination and diagnostic reporting of primary bone tumour Clin Sarcoma Res. 2011 Jul 25;1(1):6.46. Ennerking W.F., Spanier, Goodman M.A. A system for the surgical staging of musculoskeletal sarcoma.Clin Orthop Relat Res. 1980 Nov-Dec:(153):106-20.47. Ennerking W.F., A system of staging musculoskeletal neoplasms Clin Orthop Relat Res. 1986 Mar:(204):9-24.48. Steffner R.J., Jang E.S. Staging of Bone and Soft-tissue Sarcomas Am Acad Orthop Surg. 2018 Jul 1;26(13):269-278.49. Мусаев Э.Р. Первичные опухоли позвоночника // Практическая онкология. 2010. Том 11, №1. С. 19–24. 50. The TNM staging system, as described by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC), is based on evolving prognostic evidence and is now in its eighth edition [[Amin MB, Edge S, Greene F, et al., editors. AJCC cancer staging manual. 8th ed. New York (NY): Springer; 2017.]] [[Brierly JD, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 8th ed. Oxford (UK): Wiley Blackwell; 2017.51. Кушлинский Н.Е. Молекулярно-биологические исследования при опухолях костей // В кн.: «Злокачественные опухоли костей» (под ред. М.Д. Алиева). Издательская группа РОНЦ им. Н.Н. Блохина РАМН. М., 2008, с. 19–54. 52. Francannet C., Cohen-Tanugi A., Le Merrer M., Minnich A., Bonaventure J., Legeai-Mallet L. Genotype-phenotype correlation in heredoatary multiple exostoses // J. Med. Genet. 2001. Vol. 38, p. 430-434. 53. Герштейн Е.С., Щербаков А.М., Обушева М.Н., Кушлинский Н.Е. Иммуноферментное исследование содержания фактора роста эндотелия сосудов (VEGF) в опухолях и сыворотке крови больных раком молочной железы // Кремлевская медицина. 2005. №3. С. 45–52. 54. Герштейн Е.С., Щербаков А.М., Обушева М.Н., Кушлинский Н.Е. Иммуноферментное исследование содержания фактора роста эндотелия сосудов (VEGF) в опухолях и сыворотке крови больных раком молочной железы // Кремлевская медицина. 2005. №3. С. 45–52. 55. Dei Tos A.P. Classification of pleomorphic sarcomas: where are we now? Histopathology 2006. 48,51-62.